Adage Capital Management
Boston, Massachusetts, United StatesFounded 2001
Adage Capital Management focuses on S&P 500 asset management for institutional clients, such as endowments and foundations, employing long/short equity strategies driven by fundamental analysis. The firm also invests in later-stage private equity rounds, with a notable presence in the biotechnology and pharmaceutical sectors.
Portfolio
6
Fund Size
$42.0B
Top Stage
Series C
Last 12 Mo
0
Stage Distribution
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Gracell Biotechnologies Inc. | Growth | $150M | Aug 2023 |
| HawkEye 360 | Series D | $58M | Jul 2023 |
| Beckley Psytech | Series C | $80M | Aug 2021 |
| GOAT Group | Series F | $195M | Jun 2021 |
| HemoShear Therapeutics, Inc. | Series A | $40M | Feb 2021 |
| Amplyx Pharmaceuticals | Series C | $53M | May 2020 |
Top Co-Investors
Janus Henderson Investors2 shared
Sofinnova Partners1 shared
NEA (New Enterprise Associates)1 shared
Vivo Capital1 shared
Logos Capital1 shared
OrbiMed1 shared
RA Capital Management1 shared
Prime Movers Lab1 shared
Palo Santo1 shared
other private investors1 shared
Park West Asset Management1 shared
Franklin Templeton1 shared
Ulysses Management1 shared
T. Rowe Price1 shared
BlackRock1 shared
Manhattan Venture Partners1 shared
Insight Partners1 shared
NightDragon1 shared
Strategic Development Fund1 shared
Razor's Edge1 shared
Last updated: 3 March 2026